AstraZeneca PLC (LON:AZN) Receives Average Recommendation of “Moderate Buy” from Brokerages

AstraZeneca PLC (LON:AZN) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is £116.86 ($146.79).

A number of equities research analysts recently commented on AZN shares. Barclays reiterated an “overweight” rating and issued a £125 ($157.02) price objective on shares of AstraZeneca in a report on Monday, April 8th. Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, March 13th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £105 ($131.89) price target on shares of AstraZeneca in a report on Tuesday, April 23rd. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Thursday, April 4th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Monday, April 15th.

AstraZeneca Trading Up 0.3 %

LON AZN opened at £120.24 ($151.04) on Tuesday. The stock has a 50-day simple moving average of £106.10 and a 200 day simple moving average of £104.51. The company has a market capitalization of £186.37 billion, a PE ratio of 3,968.32, a P/E/G ratio of 0.89 and a beta of 0.19. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. AstraZeneca has a 12 month low of GBX 9,461 ($118.84) and a 12 month high of £124.88 ($156.86).

AstraZeneca Increases Dividend

The company also recently disclosed a dividend, which was paid on Monday, March 25th. Stockholders of record on Thursday, February 22nd were given a dividend of GBX 156 ($1.96) per share. This is a boost from AstraZeneca’s previous dividend of $71.80. This represents a dividend yield of 1.49%. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s dividend payout ratio is currently 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.